Evidence map›Paper›PMID 40872619›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

The Rise of a Legend: Lithium and the Extraordinary Story of Its Discovery.

Konstantinos N Fountoulakis

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Konstantinos N Fountoulakis3rd Department of Psychiatry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0001-5503-0811

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lithium is still the gold standard in the treatment of Bipolar disorder in adults. Despite the recent advances and the continuous increase in the use of antipsychotics and specific antiepileptics, it is still widely used despite not being promoted by the industry. Lithium was discovered in the early 19th century in a Swedish mine, and only a few decades later, it was discovered that it could be added to water so that urea could be dissolved with the formation of lithium urate. This was considered in the frame of the uric acid diathesis theory, which, during the 19th century, was considered a strong etiopathogenetic theory for many pathological conditions, including mental disorders. The first attempts to use lithium as a treatment modality in psychiatry appeared in the late 19th century by Hammond and the Lange brothers, and during the late 19th century and the early 20th century, lithium was used in various remedies and beverages until its toxicity became evident. Lithium was established as a valid treatment option for Bipolar disorder only during the second half of the 20th century after the works of John Cade, Mogens Schou, Poul Baastrup, and others who pursued a line of research, frequently against the scientific opinion of the majority of colleagues.

Indexed as

bipolar disorderdiscoveryhistorylithium

Identifiers

PMID40872619
PMCPMC12389268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.